Learn About Type A Insulin Resistance Syndrome

What is the definition of Type A Insulin Resistance Syndrome?

Type A insulin resistance syndrome is a rare disorder characterized by severe insulin resistance, a condition in which the body's tissues and organs do not respond properly to the hormone insulin. Insulin normally helps regulate blood sugar levels by controlling how much sugar (in the form of glucose) is passed from the bloodstream into cells to be used as energy. In people with type A insulin resistance syndrome, insulin resistance impairs blood sugar regulation and ultimately leads to a condition called diabetes mellitus, in which blood sugar levels can become dangerously high.

Save information for later
Sign Up
What are the causes of Type A Insulin Resistance Syndrome?

Type A insulin resistance syndrome results from mutations in the INSR gene. This gene provides instructions for making a protein called an insulin receptor, which is found in many types of cells. Insulin receptors are embedded in the outer membrane surrounding the cell, where they attach (bind) to insulin circulating in the bloodstream. This binding triggers signaling pathways that influence many cell functions.

How prevalent is Type A Insulin Resistance Syndrome?

Type A insulin resistance syndrome is estimated to affect about 1 in 100,000 people worldwide. Because females have more health problems associated with the condition, it is diagnosed more often in females than in males.

Is Type A Insulin Resistance Syndrome an inherited disorder?

Type A insulin resistance syndrome can have either an autosomal dominant or, less commonly, an autosomal recessive pattern of inheritance.

Who are the top Type A Insulin Resistance Syndrome Local Doctors?
Elite
Highly rated in
35
conditions

University Of Melbourne

Parkville, VIC, AU 

Ravi Savarirayan is in Parkville, Australia. Savarirayan is rated as an Elite expert by MediFind in the treatment of Type A Insulin Resistance Syndrome. He is also highly rated in 35 other conditions, according to our data. His top areas of expertise are Achondroplasia, Type A Insulin Resistance Syndrome, Acanthosis Nigricans, and Chondrodystrophy.

Elite
Highly rated in
14
conditions

Showa Ku

Nagoya University Graduate School Of Medicine 
Nagoya, JP 

Masaki Matsushita is in Nagoya, Japan. Matsushita is rated as an Elite expert by MediFind in the treatment of Type A Insulin Resistance Syndrome. He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Acanthosis Nigricans, Type A Insulin Resistance Syndrome, Achondroplasia, and Hypochondroplasia.

 
 
 
 
Learn about our expert tiers
Learn more
Elite
Highly rated in
23
conditions

Showa Ku

Department Of Orthopaedic Surgery, Nagoya University Graduate School Of Medicine 
Nagoya, JP 

Hiroshi Kitoh is in Nagoya, Japan. Kitoh is rated as an Elite expert by MediFind in the treatment of Type A Insulin Resistance Syndrome. He is also highly rated in 23 other conditions, according to our data. His top areas of expertise are Hypochondroplasia, Type A Insulin Resistance Syndrome, Acanthosis Nigricans, and Achondroplasia.

What are the latest Type A Insulin Resistance Syndrome Clinical Trials?
Study of the Effect of Fractional co2 Laser Versus Q Switched:NdYAG Laser in the Treatment of Acanthosis Nigricans
Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Who are the sources who wrote this article ?

Published Date:updated Last, December

Published By: National Institutes of Health

What are the Latest Advances for Type A Insulin Resistance Syndrome?
The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis.
The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial.
Tired of the same old research?
Check Latest Advances
Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.